Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers

Published September 7, 2016 Dear Editor, We read with interest your article, titled “Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers,” published in the February 2016 of ePlasty. As plastic surgeons with reconstructive practices spanning a variety of disease states (cancer, trauma, wounds), we are always interested in rigorous studies that improve the evidence base in clinical care. As you know, human acellular dermal matrices (ADMs) are very widely used in a variety of settings and are a mainstay for many of us in tissue expander–based breast reconstruction. We believe any study that demonstrates a significant difference in the clinical outcomes of different products is important. While the promotional materials for different products always claim that there are big differences between product “X” and product “Y,” there is very little clinical evidence to support this claim. The Plastic Surgery literature has very few studies that compare different ADMs “head-to-head.” The few trials that do exist are small and underpowered to detect any differences. In contrast, the current DermACELL trial is a large, rigorous head-to-head comparison, which provides plastic surgeons with some new and important insights. In this article, Walters and colleagues demonstrate superior healing rates in terms of both wound closure and reduction in wound size as compared with both conventional care and GraftJacket.1 Although not all differences were statistically significant, many were and the magnitude of the differences is difficult to ignore. Although the product GraftJacket